Angela MD McLaughlin

Angela MD McLaughlin

Auto-generated profile, based on publicly available information

Angela MD McLaughlin

Section of Infectious Diseases, Department of Medicine, Boston Medical Center, Boston, MA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2020 in International Journal of Infectious Diseases
Verified
Journal Article
Open access
PSPranay Sinha
Pranay Sinha
AMAnahita Mostaghim
Anahita Mostaghim
BBBielick Bielick
Bielick Bielick
AMAngela McLaughlin
Angela McLaughlin
DHDavidson H. Hamer
Davidson H. Hamer
MSManish Sagar
Manish Sagar
The aim of this observational study was to determine the optimal timing of interleukin-6 receptor inhibitor (IL6ri) administration for coronavirus disease 2019 (COVID-19). Patients with COVID-19 were given an IL6ri (sarilumab or tocilizumab) based on iteratively reviewed guidelines. IL6ri were initially reserved for critically ill patients, but after review, treatment was liberalized to patients with lower oxygen requirements. Patients were divided into two groups: those requiring ≤45% fraction of inspired oxygen (FiO2) (termed stage IIB) and those requiring >45% FiO2 (termed stage III) at the time of IL6ri administration. The main outcomes were all-cause mortality, discharge alive from hospital, and extubation. A total of 255 COVID-19 patients were treated with IL6ri (149 stage IIB and 106 stage III). Patients treated in stage IIB had lower mortality than those treated in stage III (adjusted hazard ratio (aHR) 0.24, 95% confidence interval (CI) 0.08-0.74). Overall, 218 (85.5%) patients were discharged alive. Patients treated in stage IIB were more likely to be discharged (aHR 1.43, 95% CI 1.06-1.93) and were less likely to be intubated (aHR 0.43, 95% CI 0.24-0.79). IL6ri administration prior to >45% FiO2 requirement was associated with improved COVID-19 outcomes. This can guide clinical management pending results from randomized controlled trials.

1 November 2023 in JAIDS Journal of Acquired Immune Deficiency Syndromes
Verified
Journal Article
Closed access
AMAngela MD McLaughlin
Angela MD McLaughlin
NLNina Lin
Nina Lin
WJWenqing Jiang
Wenqing Jiang
SLSara Lodi
Sara Lodi
DLDmitry Lioznov
Dmitry Lioznov
KSKaku So-Armah
Kaku So-Armah
Background: Delayed CD4 recovery after initiating antiretroviral therapy (ART) is a novel potential mechanism by which alcohol consumption leads to increased morbidity and mortality in people with HIV. We hypothesized that alcohol consumption at ART initiation is associated with slower CD4 recovery. Methods: We retrospectively analyzed 2 pooled longitudinal alcohol/HIV cohorts (2014–2019) in St. Petersburg, Russia. Eligible participants initiated the first ART during parent studies; had alcohol consumption assessed by the blood biomarker, phosphatidylethanol (PEth), at the last research visit before ART initiation; and had ≥1 CD4 count measurement before and after initiating ART. Participants were stratified by low, moderate, and high PEth (80 ng/mL, respectively). We used random-effects piecewise linear regression models to estimate CD4 recovery, defined as CD4 count change per 30 days after ART initiation, by the alcohol group. Results: Of 60 eligible participants, median age was 34 years and 28% were female. The median pre-ART PEth in the low, moderate, and high PEth groups were <8, 23, and 232 ng/mL, respectively. After starting ART, the CD4 count increased by 13.60 cells/mm3/mo (95% CI: 0.33 to 26.87) with low PEth, 0.93 cells/mm3/mo (95% CI: −6.18 to 8.04) with moderate PEth, and 2.33 cells/mm3/mo (95% CI: −3.44 to 8.09) with high PEth. Conclusions: Among Russians with HIV, we observed faster CD4 recovery after ART initiation in those with low alcohol consumption compared with those with moderate and high alcohol consumption, as assessed by PEth. This analysis provides further evidence for the possible value of alcohol reduction interventions for people with HIV who are initiating ART.

16 December 2022 in Medicine
Verified
Journal Article
Open access
SZSarah Zambrano
Sarah Zambrano
MDMegan Davis
Megan Davis
DLDavid R. Md Leeds
David R. Md Leeds
KNKelvin Noronha
Kelvin Noronha
AMAngela MD McLaughlin
Angela MD McLaughlin
SASabrina Assoumou
Sabrina Assoumou
Early identification of patients at risk for severe coronavirus disease 2019 (COVID-19) is crucial for appropriate triage and determination of need for closer monitoring. Few studies have examined laboratory trends in COVID-19 infection and sought to quantify the degree to which laboratory values affect mortality. We conducted a retrospective cohort (n = 407) study of hospitalized patients with COVID-19 early in the course of the pandemic, from March 16th to April 8th, 2020 and compared baseline to repeat laboratory testing 72 hours into admission. The primary outcome was death. We found that rises of 25 mg/L C-reactive protein, 50 units/L lactate dehydrogenase, and 100 ng/mL ferritin were associated with 23%, 28%, and 1% increased odds of death, respectively. In contrast, changes in fibrinogen, D-dimer, white blood cell count, and creatinine in the first few days of hospital admission were not associated with mortality. These quantitative findings may assist clinicians in determining the risk of potential clinical decline in patients with COVID-19 and influence early management.